Picture loading failed.

Anti-PDCD1 therapeutic antibody (Pre-made Toripalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-587-1mg 1mg 3090
GMP-Bios-ab-587-10mg 10mg 21890
GMP-Bios-ab-587-100mg 100mg 148000
GMP-Bios-ab-587-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-PDCD1 therapeutic antibody (Pre-made Toripalimab biosimilar,Whole mAb)
INN Name Toripalimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure6jbt:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesFudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University
Conditions ApprovedMalignant melanoma
Conditions ActiveNasopharyngeal cancer;Oesophageal cancer;Biliary cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours;Urogenital cancer;Head and neck cancer;Alveolar soft part sarcoma;Breast cancer;Cancer;Liver cancer;Lymphoma;Neuroendocrine tumours;Renal cancer
Conditions Discontinuedna
Development Techna